Insider Trading Watch List: Allergan PLC. $AGN

85c2d5c1a7703aaacb8b6cc499404e04

Allergan PLC. (NYSE:AGN) insider have most recently took part in a trading activity. On Jun 16, 2017 Saunders Brent L, Chairman, President and CEO bought 86 shares having total worth of $20,557 at the price of $239.04 per share, following the transaction a total of 131,178 shares owned by Saunders Brent L. Before this latest buy, Saunders Brent L purchased AGN at 1 other times during the past twelve months, for a total investment of $992,932 at an average of $189.13 per share.

Furthermore, over the past 12 months , the stock was traded 6 times by insiders. In 4 of these trades, the insider was a seller while an employee of the company was the buyer in 2 instances.

Shares of Allergan PLC. (NYSE:AGN) traded up 0.57% on Sep 18, 2017, hitting $221.54. 2,940,163 shares of the company’s stock traded hands. Allergan PLC. has a 52 week low of $186.78 and a 52 week high of $257.9. The company’s market cap is $94,780 million.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Aug 3, 2017. The company reported 4.02 earnings per share (EPS) for the quarter, higher than the consensus estimate of 3.93 by $0.089999999999999. The company had revenue of $4,007 million for the quarter, compared to the consensus estimate of $3,940 million. During the same quarter in the previous year, the company posted 3.35 earnings per share. The company’s revenue for the quarter was up 9% on a year-over-year basis.

2017-08-03 2017-05-09 2017-02-08 2016-11-02 2016-08-08 2016-05-10 2016-02-22 2015-11-04 2015-08-06 2015-05-11
earnings per share 4.02 3.35 3.90 3.32 3.35 3.04 3.41 3.48 4.41 4.30
Revenue(M) 4007 3573 3864 3622 3685 3796 4198 4089 5755 4203

Allergan PLC. has been the subject of a number of recent research reports. Analysts at Citigroup Maintains shares of Allergan PLC. to an Buy rating in a research note. They now have a $290.00 price target on the stock.

Actavis, Inc. was is incorporated in 1985. The company’s initial public offering was in February 1993. It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. On October 31, 2012, Watson Pharmaceuticals, Inc. completed the acquisition of the company’s Group. Watson Pharmaceuticals, Inc. common stock was traded on the New York Stock Exchange under the symbol WPI until close of trading on January 23, 2013, at which time Watson Pharmaceuticals, Inc. changed its corporate name to Actavis, Inc. and changed its ticker symbol to ACT. The Company develops and out-license generic pharmaceutical products primarily in Europe through its Medis third-party business. Following the renaming, the Company also changed the name of its three reporting segments. The Global Generics segment has become Actavis Pharma, Global Brands has become Actavis Specialty Brands, and Distribution has become Anda Distribution. The Actavis Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Actavis Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment mainly distributes generic pharmaceutical products manufactured by third parties, as well as by the Company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians’ offices. The Anda Distribution segment operating results exclude sales by Anda of products developed, acquired, or licensed by the Company’s Actavis Pharma and Actavis Specialty Brands segments. The Actavis Pharma segment develops, manufactures, markets, sells and distributes generic, branded generic and OTC products. The Actavis Specialty Brands segment includes key promoted products such as Rapaflo, Gelnique, Crinone, Trelstar, GeneressTM Fe, Androderm, and Kadian and a number of non-promoted products. All pharmaceutical manufacturers, including the Company, are subject to extensive, complex and evolving regulation by the federal government, principally the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.